Nuvation Bio (Nuvation Bio) Tax Rate %

: 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Nuvation Bio's Tax Expense for the three months ended in Dec. 2023 was $0.00 Mil. Nuvation Bio's Pre-Tax Income for the three months ended in Dec. 2023 was $-13.79 Mil. Therefore, Nuvation Bio's Tax Rate % for the quarter that ended in Dec. 2023 was 0.00%.

Nuvation Bio Tax Rate % Historical Data

The historical data trend for Nuvation Bio's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Tax Rate %

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Tax Rate %												-	-	-	-	-

Nuvation Bio Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Nuvation Bio's Tax Rate % for the fiscal year that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2023 )	/	Pre-Tax Income (A: Dec. 2023 )
	=	0	/	-75.802
	=	0.00 %

Nuvation Bio's Tax Rate % for the quarter that ended in Dec. 2023 is calculated as

Tax Rate %	=	Tax Expense (Q: Dec. 2023 )	/	Pre-Tax Income (Q: Dec. 2023 )
	=	0	/	-13.787
	=	0.00 %

Nuvation Bio Tax Rate % Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).